These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15602707)

  • 1. Barriers to adherence of deferoxamine usage in sickle cell disease.
    Treadwell MJ; Law AW; Sung J; Hackney-Stephens E; Quirolo K; Murray E; Glendenning GA; Vichinsky E
    Pediatr Blood Cancer; 2005 May; 44(5):500-7. PubMed ID: 15602707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z; Fischer R; Treadwell M; Yamashita R; Fung EB; Calvelli L; Quirolo K; Foote D; Harmatz P; Vichinsky EP
    Ann N Y Acad Sci; 2005; 1054():486-91. PubMed ID: 16339703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating adherence to highly active antiretroviral therapy into children's daily lives: a qualitative study.
    Hammami N; Nöstlinger C; Hoerée T; Lefèvre P; Jonckheer T; Kolsteren P
    Pediatrics; 2004 Nov; 114(5):e591-7. PubMed ID: 15520091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caregiving time in sickle cell disease: psychological effects in maternal caregivers.
    Moskowitz JT; Butensky E; Harmatz P; Vichinsky E; Heyman MB; Acree M; Wrubel J; Wilson L; Folkman S
    Pediatr Blood Cancer; 2007 Jan; 48(1):64-71. PubMed ID: 16622841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
    Kalpatthi R; Peters B; Kane I; Holloman D; Rackoff E; Disco D; Jackson S; Laver JH; Abboud MR
    Pediatr Blood Cancer; 2010 Dec; 55(7):1338-42. PubMed ID: 20981690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary embolism developing in patients with sickle cell disease on hypertransfusion and IV deferoxamine chelation therapy.
    Sheth S; Ruzal-Shapiro C; Hurlet-Jensen A; Piomelli S; Berdon WE
    Pediatr Radiol; 1997 Dec; 27(12):926-8. PubMed ID: 9388284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parents' perspective on symptoms, quality of life, characteristics of death and end-of-life decisions for children dying from cancer.
    Hechler T; Blankenburg M; Friedrichsdorf SJ; Garske D; Hübner B; Menke A; Wamsler C; Wolfe J; Zernikow B
    Klin Padiatr; 2008; 220(3):166-74. PubMed ID: 18478489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily living with distress and enrichment: the moral experience of families with ventilator-assisted children at home.
    Carnevale FA; Alexander E; Davis M; Rennick J; Troini R
    Pediatrics; 2006 Jan; 117(1):e48-60. PubMed ID: 16396848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical assessment of transcranial doppler screening rates in a large pediatric sickle cell center: opportunities to improve healthcare quality.
    Raphael JL; Shetty PB; Liu H; Mahoney DH; Mueller BU
    Pediatr Blood Cancer; 2008 Nov; 51(5):647-51. PubMed ID: 18623200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.
    Armstrong EP; Skrepnek GH; Sasane M; Snodgrass SM; Ballas SK
    J Med Econ; 2013; 16(1):10-8. PubMed ID: 22947171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy.
    Alvarez O; Rodriguez-Cortes H; Robinson N; Lewis N; Pow Sang CD; Lopez-Mitnik G; Paley C
    J Pediatr Hematol Oncol; 2009 Oct; 31(10):739-44. PubMed ID: 19734806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-reported level of and factors influencing the compliance to desferrioxamine therapy in multitransfused thalassaemias.
    Lee WS; Toh TH; Chai PF; Soo TL
    J Paediatr Child Health; 2011 Aug; 47(8):535-40. PubMed ID: 21392144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral and emotional problems in children with sickle cell disease and healthy siblings: Multiple informants, multiple measures.
    Hijmans CT; Grootenhuis MA; Oosterlaan J; Last BF; Heijboer H; Peters M; Fijnvandraat K
    Pediatr Blood Cancer; 2009 Dec; 53(7):1277-83. PubMed ID: 19731327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Psychosocial aspects of beta-thalassemia: distress, coping and adherence].
    Goldbeck L; Baving A; Kohne E
    Klin Padiatr; 2000; 212(5):254-9. PubMed ID: 11048284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and assessment of stroke in patients with sickle cell disease: neuropsychological functioning and magnetic resonance imaging.
    Gold JI; Johnson CB; Treadwell MJ; Hans N; Vichinsky E
    Pediatr Hematol Oncol; 2008 Jun; 25(5):409-21. PubMed ID: 18569843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing adherence and factors associated with adherence in young children with asthma.
    Burgess SW; Sly PD; Morawska A; Devadason SG
    Respirology; 2008 Jun; 13(4):559-63. PubMed ID: 18422868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relation between health-related quality of life, treatment adherence and disease severity in a paediatric sickle cell disease sample.
    Fisak B; Belkin MH; von Lehe AC; Bansal MM
    Child Care Health Dev; 2012 Mar; 38(2):204-10. PubMed ID: 21434965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. At what age do children start taking daily asthma medicines on their own?
    Orrell-Valente JK; Jarlsberg LG; Hill LG; Cabana MD
    Pediatrics; 2008 Dec; 122(6):e1186-92. PubMed ID: 19047221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.